Publications | Quarter 2
The publications below are displayed based on the publication impact factor, highest to lowest. To view the publication abstract, click on the publication title followed by the respective link.
1. Haddad, D., Dsouza, V. S., Al-Mulla, F., & Al Madhoun, A. New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment. International journal of Molecular Sciences; Jan 2024.
Impact Factor
4.9
Journal Quartile
Q2
2. Abdalla, M. A., Abubaker, J., Abu-Farha, M., Al-Khairi, I., Cherian, P., Qaddoumi, M. G., Al-Rashed, F., Thanaraj, T. A., Albatineh, A. N., & Al-Mulla, F. Investigating the Role of FABP4 in Diabetes and Obesity and the Influence of Age and Ethnicity: A Comprehensive Analysis of a Cohort from the KEDP-Study. International Journal of Molecular Sciences; Apr 2024.
Impact Factor
4.9
Journal Quartile
Q2
3. Marafie SK, Al-Mulla F, Abubaker J. mTOR: Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process. International Journal of Molecular Sciences; Jun 2024.
Impact Factor
4.9
Journal Quartile
Q2
4. Bahman, F., Al-Roub, A., Akhter, N., Al Madhoun, A., Wilson, A., Almansour, N., Al-Rashed, F., Sindhu, S., Al-Mulla, F., & Ahmad, R. TNF-α/Stearate Induced H3K9/18 Histone Acetylation Amplifies IL-6 Expression in 3T3-L1 Mouse Adipocytes. International Journal of Molecular Sciences; Jun 2024.
Impact Factor
4.9
Journal Quartile
Q2
5. Kochumon, S., Al-Sayyar, A., Jacob, T., Arefanian, H., Bahman, F., Almansour, N., Alzaid, F., Al-Mulla, F., Sindhu, S., & Ahmad, R. IL-1β-Induced CXCL10 Expression in THP-1 Monocytic Cells Involves the JNK/c-Jun and NF-κB-Mediated Signaling. Pharmaceuticals; Jun 2024.
Impact Factor
4.3
Journal Quartile
Q2
6. Alotaibi, A., Karam, M., Roto, A., Alshuaib, S., Alrabah, F., & Alali, A. The first retinoblastoma local experience in Kuwait: A retrospective case series. American Journal of Ophthalmology Case Reports; Jan 2024.
Impact Factor
4.1
Journal Quartile
Q2
7. Bosso, M., Haddad, D., Al Madhoun, A., & Al-Mulla, F. Targeting the Metabolic Paradigms in Cancer and Diabetes. Biomedicines; Jan 2024.
Impact Factor
3.9
Journal Quartile
Q2
8. Ghosh, A., Leung, Y. H., Yu, J., Sladek, R., Chénier, I., Oppong, A. K., Peyot, M. L., Madiraju, S. R. M., Al-Khairi, I., Thanaraj, T. A., Abubaker, J., Al-Mulla, F., Prentki, M., & Abu-Farha, M. Silencing ANGPTL8 reduces mouse preadipocyte differentiation and insulin signaling. Biochimica et Biophysica Acta – Molecular and Cell Biology of Lipids; Apr 2024.
Impact Factor
3.9
Journal Quartile
Q2
9. Al-Onaizi, M., Braysh, K., Alkafeef, S. S., Altarrah, D., Dannoon, S., Alasousi, D., Adel, H., Kandari, A., Najem, R., Nizam, R., Williams, M. R., John, S., Thanaraj, T. A., Ahmad, R., Al-Hussaini, H., Al-Mulla, F., & Alzaid, F. Glucose intolerance induces anxiety-like behaviors independent of obesity and insulin resistance in a novel model of nutritional metabolic stress. Nutritional Neuroscience; Feb 2024.
Impact Factor
3.6
Journal Quartile
Q2
10. Al Awaidy, S., Tohme, … Mahomed, O. Elimination of Mother-to-Child Transmission of Hepatitis B Virus in Gulf Cooperation Council Countries: Current Status and Future Prospects. American J of Tropical Med & Hygiene; Jan 2024.
Impact Factor
3.6
Journal Quartile
Q2
10. Al Awaidy, S., Tohme, … Mahomed, O. Elimination of Mother-to-Child Transmission of Hepatitis B Virus in Gulf Cooperation Council Countries: Current Status and Future Prospects. American J of Tropical Med & Hygiene; Jan 2024.
Impact Factor
3.6
Journal Quartile
Q2
11. Nagar P, … Malik MZ, et al. Plasmodium falciparum cysteine protease Falcipain 3: A potential enzyme for proteolytic processing of histone acetyltransferase PfGCN5. Biotechnology and Applied Biochemistry; Jun 2024.
Impact Factor
3.2
Journal Quartile
Q2
12. Ali H, Malik MZ, Abu-Farha M, Abubaker J, Cherian P, Al-Khairi I, Nizam R, Jacob S, Bahbahani Y, Al Attar A, Thanaraj TA, Al-Mulla F. Dysregulated Urinary Extracellular Vesicle Small RNAs in Diabetic Nephropathy: Implications for Diagnosis and Therapy. Journal of Endocrine Society; Jun 2024.
Impact Factor
3.0
Journal Quartile
Q2
13. Al-Muhaiteeb, A., Alahmad, B., Abu-Farha, M., Abubaker, J., Thanaraj, T. A., Ali, H., Al-Mulla, F., & Qaddoumi, M. Long-Term Mortality and SGLT2 Inhibitors in Type 2 Diabetes with and without Renal Impairment: An Observational Cohort Study. Medical Principles and Practice; Feb 2024.
Impact Factor
2.9
Journal Quartile
Q2
14. Dashti, M., Malik, M. Z., Nizam, R., Jacob, S., Al-Mulla, F., & Thanaraj, T. A. Evaluation of HLA typing content of next-generation sequencing datasets from family trios and individuals of arab ethnicity. Frontiers in Genetics; May 2024.
Impact Factor
2.8
Journal Quartile
Q2
15. Abdalla, M. A., Ssemmondo, E., et al. Advancements in the management of obesity: a review of current evidence and emerging therapies. Expert Review of Endocrinology & Metabolism; May 2024.
Impact Factor
2.7
Journal Quartile
Q2
16. Badacho, A. S., … & Mahomed, O. H. Mapping evidence on barriers to and facilitators of diagnosing noncommunicable diseases among people living with human immunodeficiency virus in low- and middle-income countries in Africa: A scoping review. SAGE Open Medicine; May 2024.
Impact Factor
2.3
Journal Quartile
Q2
17. Ali, I., Haddad, D., et al. Quality of life and nutritional status in peritoneal dialysis patients: a cross-sectional study from Palestine. BMC Nephrology; Jan 2024.
Impact Factor
2.2
Journal Quartile
Q2
18. Alahmad B, Yuan Q, Achilleos S, Salameh P, Papatheodorou SI, Koutrakis P. Evaluating the temperature-mortality relationship over 16 years in Cyprus. Journal of the Air and Waste Management Association; Jun 2024.
Impact Factor
2.1
Journal Quartile
Q2
19. Al-Ozairi, E., Narula, K., Miras, A. D., Taghadom, E., Samad, A. E., Al Kandari, J., Alyosef, A., Mashankar, A., Al-Najim, W., & le Roux, C. W. Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial). Trials; Feb 2024.
Impact Factor
2.0
Journal Quartile
Q2
